<DOC>
	<DOCNO>NCT02919475</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability pharmacokinetics ( PK ) JTE-051 administer 12 week subject active rheumatoid arthritis receive background non-biologic disease-modifying anti-rheumatic drug therapy .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety Tolerability JTE-051 Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>A diagnosis RA prior Screening Visit . Active disease despite ongoing therapy two nonbiologic diseasemodifying antirheumatic drug , include methotrexate Screening Baseline Visits . Screening hsCRP â‰¥1.2 x upper limit normal ( ULN ) . Prior/current exposure biologic and/or kinase inhibitor therapy . Known history presence polyneuropathy cause presence clinically active compression neuropathy , radiculopathy plexopathy Screening Visit . Positive test result human immunodeficiency ( HIV ) virus , hepatitis B virus hepatitis C ( HCV ) virus Screening Visit . Positive drug abuse alcohol test result . History clinicallysignificant infection require oral antimicrobial antiviral therapy within 8 week prior Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>JTE-051</keyword>
	<keyword>Active Rheumatoid Arthritis</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>